Platinum complexes as potential antineoplastic drugs
Kuduk-Jaworska, J.
Postepy Higieny i Medycyny Doswiadczalnej 38(3): 281-322
1984
ISSN/ISBN: 0032-5449 PMID: 6398870 Document Number: 230699
Document emailed within 1 workday
Related Documents
Hacker, M.P.; Khokhar, A.R.; Krakoff, I.H.; Brown, D.B.; McCormack, J.J. 1986: Water-soluble N-substituted iminodiacetato(1,2-diaminocyclohexane)-platinum(II) complexes as potential antitumor agents Cancer Research 46(12 Part 1): 6250-6254Endo, K.; Akamatsu, K.; Matsumoto, T.; Morikawa, K.; Koizumi, M.; Mitsui, H.; Koizumi, K. 1992: Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice Anticancer Research 12(1): 49-58
Gallelli, J.F. 1982: Evaluating the potential hazard of handling antineoplastic drugs American Journal of Hospital Pharmacy 39(11): 1877
Siddik, Z.H.; Thai, G.; Yoshida, M.; Zhang, Y.P.; Khokhar, A.R. 1994: Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo Anti-Cancer Drug Design 9(6): 495-509
Stoychkov, J.; Dämianova, M. 1977: Hamster apigmented melanoma as a model for screening of potential antineoplastic drugs Neoplasma 24: 161-164
Wrześniok, D.; Buszman, E.; Matusiński, B. 2003: Drugs ototoxicity. Part II. Loop diuretics, nonsteroidal anti-inflammatory drugs, antineoplastic and antimalarial drugs Wiadomosci Lekarskie 56(7-8): 369-374
Ross, S.A.; Carr, C.A.; Brïet, J.W.; Lowe, G. 2000: Transfer of 4'-chloro-2,2':6',2"-terpyridine platinum(II) between human serum albumin, glutathione and other thiolate ligands. a possible selective natural transport mechanism for the delivery of platinum(II) drugs to tumour cells Anti-Cancer Drug Design 15(6): 431-439
Dominici, C.; Petrucci, F.; Alimonti, A.; La Torre, F.; Cifani, A.; Caroli, S. 1995: Platinum-based antineoplastic agents: biomedical applications and therapeutic aspects Annali Dell'istituto Superiore di Sanita 31(2): 289-294
Rosenberg, B. 1975: Possible mechanisms for the antitumor activity of platinum coordination complexes Cancer ChemoTherapy Reports 59(3): 589-598
Trissel, L.A.; Parks, N.P.; Santiago, N.M. 1991: Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection American Journal of Hospital Pharmacy 48(10): 2186-2189
Romanowska, K.; Kuduk-Jaworska, J. 1991: Relationship between topological properties and biological activity of platinum (II) complexes Archivum Immunologiae et Therapiae Experimentalis 39(1-2): 75-84
Leopold, W.R.; Batzinger, R.P.; Miller, E.C.; Miller, J.A.; Earhart, R.H. 1981: Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane Cancer Research 41(11 Part 1): 4368-4377
Kidani, Y.; Noji, M.; Tsukagoshi, S.; Tashiro, T. 1978: Antitumor activity of water-soluble platinum(II) complexes of 1,2-cyclohexanediamine isomers Gan 69(2): 263-265
Herman, T.S.; Teicher, B.A.; Collins, L.S. 1988: Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures Cancer Research 48(9): 2342-2347
Papageorgiou, A.; Iakovidou, Z.; Mourelatos, D.; Mioglou, E.; Boutis, L.; Kotsis, A.; Kovala-Demertzi, D.; Domopoulou, A.; West, D.X.; Dermetzis, M.A. 1997: Antineoplastic and cytogenetic effects of complexes of Pd (II) with 4N-substituted derivatives of 2-acetyl-pyridine-thiosemicarbazone Anticancer Research 17(1a): 247-251
Prajda, N.; Kralovánszky, J.; Gal, F.; Kiss, F.; Kerpel-Fronius, S. 1989: Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow In Vivo 3(4): 267-270
Mailliet, P.; Segal-Bendirdjian, E.; Kozelka, J.; Barreau, M.; Baudoin, B.; Bissery, M.C.; Gontier, S.; Laoui, A.; Lavelle, F.; Le Pecq, J.B. 1995: Asymmetrically substituted ethylenediamine platinum(II) complexes as antitumor agents: synthesis and structure-activity relationships Anti-Cancer Drug Design 10(1): 51-73
Bournique, C.P.; Chottard, J.C.; Deysson, G. 1975: Antimitotic properties of platinum (II) complexes of the type trans PtC12 (olefin) (pyridine). Study by means of the Allium test Annales Pharmaceutiques Francaises 33(2): 77-84
Ohno, S.; Strebel, F.R.; Stephens, L.C.; Siddik, Z.H.; Makino, M.; Klostergaard, J.; Tomasovic, S.P.; Khokhar, A.R.; Bull, J.M. 1992: Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats Cancer Research 52(15): 4096-4101
Orfi, L.; Wáczek, F.; Szabó, M.; Kövesdi, I.; Mészáros, G.; Idei, M.; Horváth, A.; Hollósy, F.; Mák, M.; Szegedi, Z.; Szende, B.; Kéri, G.; Noszál, B. 1999: Preparation and characterization of potential antineoplastic agents Acta Pharmaceutica Hungarica 69(3): 115-122